GlassScriptPhysician profile
Ankit P Patel
NPI 1871941385
$1,770.35
in general payments reported to CMS, 2019-2025
19 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $101 · 2021: $539 · 2022: $457 · 2023: $147 · 2024: $51.95 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $491.59 | 2020-2025 | Proclaim, Acculink, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $319.83 | 2021-2023 | Xarelto |
| Melinta Therapeutics, LLC | $151.29 | 2021-2022 | |
| United Therapeutics Corporation | $124.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.19 | 2021 | |
| Vifor Pharma, INC. | $80.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.93 | 2022-2023 | |
| Pfizer INC. | $69.96 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $68.19 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $56.77 | 2022-2023 | Rebyota |
| Gilead Sciences, INC. | $32.16 | 2022-2023 | Veklury |
| Novo Nordisk INC | $26.86 | 2019 | |
| Boston Scientific Corporation | $24.17 | 2021 | |
| Abbvie INC. | $19.95 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $17.99 | 2020 | |
| Dentsply Sirona INC | $12.87 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.79 | 2019 | |
| Nabriva Therapeutics, Plc | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.